Proactive Investors - Run By Investors For Investors

Medlab Clinical does deal for global distribution of NanaBis

The development and distribution deal is in the form of a heads of agreement.
collaboration concept
The HoA is with Canada’s fourth largest generic pharmaceutical company

Medlab Clinical Ltd (ASX:MDC) has entered an agreement with Canadian pharmaceutical company, Pharmascience Inc. for the further development and global distribution of NanaBis.

The terms of the HoA provide for both parties to negotiate various research, regulatory and commercial milestones involving potential global territories for NanaBis.

READ: Medlab Clinical takes EMA and FDA approval track as cannabis research continues

NanaBis is a highly purified proprietary blend of cannabis molecules cannabidiol (CBD) and tetrahydrocannabinol (THC).

It is delivered into the body using Medlab’s patented sub-micron delivery platform NanoCelle.

NanaBis is a buccal (side of cheek) spray currently in the second stage of an Australian advanced cancer pain trial.

Patients can access it under the government’s Special Access Scheme and it is currently before several regulatory agencies for potential fast track drug approval pathways.

Medlab’s CEO Dr Sean Hall said: “NanaBis is in an exciting stage of its development as the company looks to fast track global drug approval pathways.

This Heads of Agreement signifies real intent and interest for a true global pharmaceutical company to enter legitimate science as it relates to cannabis that has been research focused into a serious condition: cancer pain.

Collaborating with global companies allows faster expansion

Dr Hall added: “being able to collaborate with global pharmaceutical companies like Pharmascience Inc. allows MDC the opportunity to expand NanaBis quicker in global territories including USA and Canada”.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full MDC profile View Profile

Medlab Clinical Ltd Timeline

Related Articles

cannabis plant
March 08 2019
The Vancouver company's recent move into Jamaica, which covers the acquisition of 145 acres of cultivation property, will pave the way for the development of cannabis brands for the island nation
Sydney Harbour Bridge
January 22 2019
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.
cannabis facility
January 23 2019
The company is breaking into the large and lucrative market in the golden state
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use